MannKind Investor Relations Material
Latest events
Q1 2025
MannKind
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from MannKind Corporation
Access all reports
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for patients with diabetes and pulmonary diseases. The company’s flagship product is an inhalable insulin used to manage blood sugar levels in adults with diabetes. MannKind is also exploring its proprietary Technosphere platform for the delivery of other therapeutic agents via inhalation, aiming to improve treatment options for various chronic conditions. The company is headquartered in Danbury, Connecticut, and its shares are listed on the NASDAQ.
Key slides for MannKind Corporation
Q2 2024
MannKind Corporation
Q2 2024
MannKind Corporation
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
MNKD
Country
🇺🇸 United States